Traws Pharma Inc (TRAW)
Traws Pharma Inc is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker TRAW. The company focuses on developing small-molecule oral drug candidates for respiratory viral diseases and cancer. Its pipeline includes TRX01 (Ratutrelvir), an investigational treatment for COVID-19 designed to address treatment resistance, and Tivoxavir marboxil, an endonuclease inhibitor being studied for bird flu and seasonal influenza. In oncology, Traws Pharma is advancing narazaciclib for solid tumors and hematological malignancies, as well as rigosertib, which is being investigated alone and in combination across multiple cancer settings. The company has licensing arrangements with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. Formerly known as Onconova Therapeutics, Inc., the company adopted its current name in April 2024 and is headquartered in Newtown, Pennsylvania.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TRAW
|
$0.83
|
33.1% Upside
|
Undervalued
|
$1
|
60.5% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-0.7x
|
-1.8x
|
3.5x
|
9.253 M
|
6.306 M
|
0.0%
|
77.4%
|
-171.8
|
—
|
110.2%
|
